ICD-10-CM Billable Code

C26.1

Malignant neoplasm of spleen

Clinical Classification Guidelines

Excludes Type 1

  • Hodgkin lymphoma (C81.-)
  • non-Hodgkin lymphoma (C82-C85)

Medical Intelligence & Overview

Malignant neoplasm of the spleen, also known as splenic cancer, is a rare type of cancer characterized by the uncontrolled growth of malignant cells in the spleen. The spleen is an organ located in the upper left abdomen, playing a critical role in the immune system and blood filtration. Due to its rarity and subtle symptoms, early diagnosis can be challenging. This condition requires careful medical evaluation and management to address the cancerous growth effectively.

Causes & Symptoms

Clinical Causes: Exact causes of splenic malignancies are not well understood, but risk factors may include genetic predispositions. In some cases, it may be associated with other hematologic cancers like lymphoma. History of exposure to radiation or certain chemicals can increase the risk. Chronic immune system disorders might contribute to the development of splenic tumors. Previous or ongoing cancer treatments may also be related to secondary spleen neoplasms.

Key Symptoms: Unexplained weight loss Persistent fever or night sweats Left upper abdominal pain or discomfort Feeling of fullness after small meals due to spleen enlargement Palpable mass in the abdomen (in some cases) Fatigue and weakness Anemia or unusual blood counts

Diagnostic & Treatment

Diagnosis Path: Diagnosing malignant neoplasm of the spleen typically involves a combination of medical history evaluation, physical examination, and diagnostic tests. Imaging techniques such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI) are used to visualize the spleen and identify tumors. A definitive diagnosis often requires a biopsy, where a tissue sample is examined microscopically to confirm malignancy. Additional blood tests might be conducted to assess overall health and detect any related blood disorders.

Treatment Protocols: Treatment options for splenic malignancies depend on the size, location, and stage of the tumor, as well as the patient's overall health. Common approaches include: - Surgical removal of the spleen (splenectomy): This is often the primary treatment to eliminate the tumor. - Chemotherapy: Used to destroy remaining cancer cells and address systemic disease. - Radiotherapy: May be employed to target localized tumors or reduce symptoms. - Targeted therapy and immunotherapy: Emerging treatments that focus on specific cancer cell characteristics. - Supportive care: Managing symptoms and preventing complications, especially if the spleen cannot be fully removed. A multidisciplinary team of healthcare specialists typically develops a personalized treatment plan tailored to the patient's needs.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C26.1 a billable ICD-10 code?
Yes, C26.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C26.1?
Clinical documentation must specify the nature of Malignant neoplasm of spleen and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Related Diagnosis Codes

Clinical Meta Tags

neoplasm malignant spleen